be more effective than CBT alone, investigating the studies conducted on patients with anxiety disorders (PD, OCD, SAD and SP). In a meta-analysis study [34] investigating the other studies, it has been revealed that DCS reduces the fear in animals and human beings in CBT sessions of anxiety disorders. DCS effectiveness has been reported to be dependent on dose, time and length of usage period, as well. In a review article [13] it is suggested that using acute dosing of DCS in anxiety disorders (SP and SAD) can be far more effective and that a treatment plan with acute dosing would be much better than one with chronic dosing. However, the treatment plan in the present study including 50 mgs of DCS in patients with anxiety disorders coupled with 4 sessions of CBT, weekly, showed no difference in obtained results between the study groups.
SAD is among the common anxiety disorders in adolescents. The recent treatment including the combination of CBT and drug therapy is to decrease the symptoms of this disorder. [35, 36] In a Randomized Double-blind Placebo-controlled study, Hofmann et al. [13] have investigated the effect of DCS on 27 patients with SAD and revealed that anxiety disorder has been observed in DCS-receptor group to be in a significantly lesser extent than in the control group. Furthermore, in a study in the United States, 50 mgs of DCS together with CBT in patients with SAD decreased the symptoms of SAD in DCS-receptor group more than in the control group.
[28] In the present study, there were 10 patients with SAD in the case group and 12 patients with the same disorder in the control group. However, no significant difference (improvement) was observed in patients' condition between two groups after the treatment protocol was completed. These results are different those studies mentioned before. The differences in results probably is due to difference in treatment protocol or perhaps because patients in foregoing studies have been merely with SAD, while, in the present study, in addition to SAD, some other anxiety disorders have been observed in patients.
Storch et al. [36] have investigated the effect of DCS on 24 adults with the OCD. They held 12 sessions of CBT, weekly for all patients. Four hours before each session of which the patients of the case group received 250-mg DCS capsules, while the patients of the control group received placebo. Based on the result of their study, there has been no significant difference in respect to the variables between groups. Moreover, in another study, Storch et al. [37] prescribed 25-and 50-mg DCS capsules for 30 adolescents with OCD, based on their weights and 1 h before CBT. The results of their study, also, showed no significant difference between two groups. In another study, Wilhelm et al. [38] evaluated the effect of 100 mgs of DCS, an hour before each session of CBT (10 sessions) and revealed that there was a significant improvement in DCS-receptor group, in comparison to the control group. The present study is conducted on patients with various types of anxiety disorders in which there are 4 patients with OCD in the case group and 7 patients with the same disorder in the control group. No significant improvement in patients' condition were observed between two groups after prescribing 50 mgs of DCS, an hour before CBT sessions (4 sessions) and during one month of treatment. These results have been similar to those of Storch et al. [36] and Storch (2010) et al. [37] studies and different from those of Wilhelm et al.'s.
[38] However, treatment protocols of all of these studies have been different from one another. In addition, a fewer number of studied patients in the present study have been with OCD compared with those in above-stated ones.
Similar to the results of previous studies on the patients with anxiety disorder [27, 28] and to those of other conducted studies on the patients with Alzheimer's disease, [39] no specific side effects were observed among the patients of DCS-receptor group in this study. This similarity shows that there is not any significant difference in different doses of DCS between the case and placebo group in respect to the occurrence of side effects.
Based on the type of anxiety disorder in study groups, the low number of samples can be considered as one of the limitation of the present study, indicating that this small number of samples would not be sufficient to show the difference between groups based on the type of the anxiety disorder. In the present study, however, the number of samples was calculated based on the study aim, which is to investigate the effect of DCS on improving the symptoms of patients with anxiety disorders, which can investigate the effect of DCS on patients with simultaneously several anxiety disorders. Therefore, future studies are recommended to be designed according to the frequency distribution of types of anxiety disorders or on patients developing a specific anxiety disorder with specific sample size.
Conclusion
As a whole, the results of the present study revealed that there has been no difference in symptoms improvement in adolescent patients with anxiety disorder who received treatment protocol including 4 sessions of CBT, weekly, together with 50 mgs of DCS, compared to the patients of the control group. However, considering the difference in the results of various studies with different treatment protocols, conducting more studies in this respect seems to be necessary.
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